Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Tumour-targeting ADCs: delivering the anti-cancer warhead

Antibody-drug conjugates combine the efficacy of cytotoxic drugs and the tumour-specific targeting of antibodies to maximise anti-cancer potency and minimise side effects. Chris Lo talks to experts in the field of ADC development to discover the potential of this burgeoning treatment type, and the challenges involved in getting it right.

Free download worth over $5000
Download our 2018 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global technology, media and telecoms

Go Top